Eric Nisenbaum - Publications

Affiliations: 
Lilly, Lilly, PA, United States 

53 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Tan ZY, Priest BT, Krajewski JL, Knopp KL, Nisenbaum ES, Cummins TR. Protein kinase C enhances human sodium channel hNav1.7 resurgent currents via a serine residue in the domain III-IV linker. Febs Letters. 588: 3964-9. PMID 25240195 DOI: 10.1016/j.febslet.2014.09.011  1
2014 Tan ZY, Piekarz AD, Priest BT, Knopp KL, Krajewski JL, McDermott JS, Nisenbaum ES, Cummins TR. Tetrodotoxin-resistant sodium channels in sensory neurons generate slow resurgent currents that are enhanced by inflammatory mediators. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 7190-7. PMID 24849353 DOI: 10.1523/JNEUROSCI.5011-13.2014  1
2013 Zanotti-Fregonara P, Barth VN, Zoghbi SS, Liow JS, Nisenbaum E, Siuda E, Gladding RL, Rallis-Frutos D, Morse C, Tauscher J, Pike VW, Innis RB. 11C-LY2428703, a positron emission tomographic radioligand for the metabotropic glutamate receptor 1, is unsuitable for imaging in monkey and human brains. Ejnmmi Research. 3: 47. PMID 23758896 DOI: 10.1186/2191-219X-3-47  1
2013 Upadhyaya HP, Desaiah D, Schuh KJ, Bymaster FP, Kallman MJ, Clarke DO, Durell TM, Trzepacz PT, Calligaro DO, Nisenbaum ES, Emmerson PJ, Schuh LM, Bickel WK, Allen AJ. A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder. Psychopharmacology. 226: 189-200. PMID 23397050 DOI: 10.1007/s00213-013-2986-z  1
2013 Zanotti-Fregonara P, Barth VN, Liow JS, Zoghbi SS, Clark DT, Rhoads E, Siuda E, Heinz BA, Nisenbaum E, Dressman B, Joshi E, Luffer-Atlas D, Fisher MJ, Masters JJ, Goebl N, et al. Evaluation in vitro and in animals of a new 11C-labeled PET radioligand for metabotropic glutamate receptors 1 in brain. European Journal of Nuclear Medicine and Molecular Imaging. 40: 245-53. PMID 23135321 DOI: 10.1007/s00259-012-2269-7  1
2012 Kato AS, Knierman MD, Siuda ER, Isaac JT, Nisenbaum ES, Bredt DS. Glutamate receptor δ2 associates with metabotropic glutamate receptor 1 (mGluR1), protein kinase Cγ, and canonical transient receptor potential 3 and regulates mGluR1-mediated synaptic transmission in cerebellar Purkinje neurons. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 15296-308. PMID 23115168 DOI: 10.1523/JNEUROSCI.0705-12.2012  1
2012 Fisher MJ, Backer RT, Barth VN, Garbison KE, Gruber JM, Heinz BA, Iyengar S, Hollinshead SP, Kingston A, Kuklish SL, Li L, Nisenbaum ES, Peters SC, Phebus L, Simmons RM, et al. 3-Phenyl-5-isothiazole carboxamides with potent mGluR1 antagonist activity. Bioorganic & Medicinal Chemistry Letters. 22: 2514-7. PMID 22386665 DOI: 10.1016/j.bmcl.2012.02.003  1
2011 Timm DE, Benveniste M, Weeks AM, Nisenbaum ES, Partin KM. Structural and functional analysis of two new positive allosteric modulators of GluA2 desensitization and deactivation. Molecular Pharmacology. 80: 267-80. PMID 21543522 DOI: 10.1124/mol.110.070243  1
2011 Knopp KL, Nisenbaum ES, Arneric SP. Evolving cancer pain treatments: rational approaches to improve the quality of life for cancer patients. Current Pharmaceutical Biotechnology. 12: 1627-43. PMID 21466450  1
2011 Yan LZ, Johnson KW, Rothstein E, Flora D, Edwards P, Li B, Li J, Lynch R, Vaughn R, Clemens-Smith A, McCarty D, Chow C, McKnight KL, Lu J, Nisenbaum ES, et al. Discovery of potent, cyclic calcitonin gene-related peptide receptor antagonists. Journal of Peptide Science : An Official Publication of the European Peptide Society. 17: 383-6. PMID 21412957 DOI: 10.1002/psc.1358  1
2011 Caraci F, Molinaro G, Battaglia G, Giuffrida ML, Riozzi B, Traficante A, Bruno V, Cannella M, Merlo S, Wang X, Heinz BA, Nisenbaum ES, Britton TC, Drago F, Sortino MA, et al. Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective. Molecular Pharmacology. 79: 618-26. PMID 21159998 DOI: 10.1124/mol.110.067488  1
2010 Kato AS, Gill MB, Ho MT, Yu H, Tu Y, Siuda ER, Wang H, Qian YW, Nisenbaum ES, Tomita S, Bredt DS. Hippocampal AMPA receptor gating controlled by both TARP and cornichon proteins. Neuron. 68: 1082-96. PMID 21172611 DOI: 10.1016/j.neuron.2010.11.026  1
2010 Schuelert N, Zhang C, Mogg AJ, Broad LM, Hepburn DL, Nisenbaum ES, Johnson MP, McDougall JJ. Paradoxical effects of the cannabinoid CB2 receptor agonist GW405833 on rat osteoarthritic knee joint pain. Osteoarthritis and Cartilage / Oars, Osteoarthritis Research Society. 18: 1536-43. PMID 20863899 DOI: 10.1016/j.joca.2010.09.005  1
2010 Kato AS, Gill MB, Yu H, Nisenbaum ES, Bredt DS. TARPs differentially decorate AMPA receptors to specify neuropharmacology. Trends in Neurosciences. 33: 241-8. PMID 20219255 DOI: 10.1016/j.tins.2010.02.004  1
2010 Nisenbaum ES, Witkin JM. Positive allosteric modulation of AMPA receptors: A Novel potential antidepressant Therapy Milestones in Drug Therapy. 39-56. DOI: 10.1007/978-3-0346-0241-9_3  1
2008 Kato AS, Siuda ER, Nisenbaum ES, Bredt DS. AMPA receptor subunit-specific regulation by a distinct family of type II TARPs. Neuron. 59: 986-96. PMID 18817736 DOI: 10.1016/j.neuron.2008.07.034  1
2007 Siuda ER, Quirk JC, Nisenbaum ES. Methods for evaluation of positive allosteric modulators of glutamate AMPA receptors. Methods in Molecular Biology (Clifton, N.J.). 403: 37-57. PMID 18827986 DOI: 10.1007/978-1-59745-529-9_3  1
2007 Kato AS, Zhou W, Milstein AD, Knierman MD, Siuda ER, Dotzlaf JE, Yu H, Hale JE, Nisenbaum ES, Nicoll RA, Bredt DS. New transmembrane AMPA receptor regulatory protein isoform, gamma-7, differentially regulates AMPA receptors. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 4969-77. PMID 17475805 DOI: 10.1523/JNEUROSCI.5561-06.2007  1
2007 Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, Herin MF, Monn JA, McKinzie DL, Schoepp DD. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039). The Journal of Pharmacology and Experimental Therapeutics. 321: 308-17. PMID 17204749 DOI: 10.1124/jpet.106.110809  1
2007 O'Neill MJ, Messenger MJ, Lakics V, Murray TK, Karran EH, Szekeres PG, Nisenbaum ES, Merchant KM. Neuroreplacement, growth factor, and small molecule neurotrophic approaches for treating Parkinson's disease. International Review of Neurobiology. 77: 179-217. PMID 17178475 DOI: 10.1016/S0074-7742(06)77006-4  1
2006 Bleakman D, Alt A, Nisenbaum ES. Glutamate receptors and pain. Seminars in Cell & Developmental Biology. 17: 592-604. PMID 17110139 DOI: 10.1016/j.semcdb.2006.10.008  1
2006 Fernandez MC, Castaño A, Dominguez E, Escribano A, Jiang D, Jimenez A, Hong E, Hornback WJ, Nisenbaum ES, Rankl N, Tromiczak E, Vaught G, Zarrinmayeh H, Zimmerman DM. A novel class of AMPA receptor allosteric modulators. Part 1: design, synthesis, and SAR of 3-aryl-4-cyano-5-substituted-heteroaryl-2-carboxylic acid derivatives. Bioorganic & Medicinal Chemistry Letters. 16: 5057-61. PMID 16879964 DOI: 10.1016/j.bmcl.2006.07.035  1
2006 Zarrinmayeh H, Tromiczak E, Zimmerman DM, Rankl N, Ho KH, Dominguez E, Castaño A, Escribano A, Fernandez C, Jimenez A, Hornback WJ, Nisenbaum ES. A novel class of positive allosteric modulators of AMPA receptors: design, synthesis, and structure-activity relationships of 3-biphenyl-4-yl-4-cyano-5-ethyl-1-methyl-1H-pyrrole-2-carboxylic acid, LY2059346. Bioorganic & Medicinal Chemistry Letters. 16: 5203-6. PMID 16872827 DOI: 10.1016/j.bmcl.2006.07.012  1
2006 Alt A, Nisenbaum ES, Bleakman D, Witkin JM. A role for AMPA receptors in mood disorders. Biochemical Pharmacology. 71: 1273-88. PMID 16442080 DOI: 10.1016/j.bcp.2005.12.022  1
2005 O'Neill MJ, Murray TK, Clay MP, Lindstrom T, Yang CR, Nisenbaum ES. LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease. Cns Drug Reviews. 11: 77-96. PMID 15867954  1
2005 Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, McKinzie DL, Nisenbaum ES, Tizzano JP, Schoepp DD. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology. 179: 271-83. PMID 15717213 DOI: 10.1007/s00213-004-2099-9  1
2004 Quirk JC, Siuda ER, Nisenbaum ES. Molecular determinants responsible for differences in desensitization kinetics of AMPA receptor splice variants. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 11416-20. PMID 15601947 DOI: 10.1523/JNEUROSCI.2464-04.2004  1
2004 Johnson MP, Nisenbaum ES, Large TH, Emkey R, Baez M, Kingston AE. Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists. Biochemical Society Transactions. 32: 881-7. PMID 15494040 DOI: 10.1042/BST0320881  1
2004 O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES. AMPA receptor potentiators for the treatment of CNS disorders. Current Drug Targets. Cns and Neurological Disorders. 3: 181-94. PMID 15180479 DOI: 10.2174/1568007043337508  1
2003 Quirk JC, Nisenbaum ES. Multiple molecular determinants for allosteric modulation of alternatively spliced AMPA receptors. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 10953-62. PMID 14645491  1
2003 Murray TK, Whalley K, Robinson CS, Ward MA, Hicks CA, Lodge D, Vandergriff JL, Baumbarger P, Siuda E, Gates M, Ogden AM, Skolnick P, Zimmerman DM, Nisenbaum ES, Bleakman D, et al. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. 306: 752-62. PMID 12730350 DOI: 10.1124/jpet.103.049445  1
2003 Zhai Y, George CA, Zhai J, Nisenbaum ES, Johnson MP, Nisenbaum LK. Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 28: 45-52. PMID 12496939 DOI: 10.1038/sj.npp.1300013  1
2002 Quirk JC, Linden AM, Strakhova M, Yu H, Skolnick P, Nisenbaum ES. A single residue contributes sensitivity to allosteric modulation of AMPA receptors by LY395153. European Journal of Pharmacology. 454: 125-9. PMID 12421639 DOI: 10.1016/S0014-2999(02)02491-3  1
2002 Quirk JC, Nisenbaum ES. LY404187: a novel positive allosteric modulator of AMPA receptors. Cns Drug Reviews. 8: 255-82. PMID 12353058  1
2002 Zhai J, Tian MT, Wang Y, Yu JL, Köster A, Baez M, Nisenbaum ES. Modulation of lateral perforant path excitatory responses by metabotropic glutamate 8 (mGlu8) receptors. Neuropharmacology. 43: 223-30. PMID 12213276 DOI: 10.1016/S0028-3908(02)00087-4  1
2001 Harvey SC, Köster A, Yu H, Skolnick P, Baumbarger P, Nisenbaum ES. AMPA receptor function is altered in GLUR2-deficient mice. Journal of Molecular Neuroscience : Mn. 17: 35-43. PMID 11665861 DOI: 10.1385/JMN:17:1:35  1
2001 Baumbarger PJ, Muhlhauser M, Zhai J, Yang CR, Nisenbaum ES. Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal cortical pyramidal neurons by a novel allosteric potentiator. The Journal of Pharmacology and Experimental Therapeutics. 298: 86-102. PMID 11408529  1
2001 Baumbarger P, Muhlhauser M, Yang CR, Nisenbaum ES. LY392098, a novel AMPA receptor potentiator: electrophysiological studies in prefrontal cortical neurons. Neuropharmacology. 40: 992-1002. PMID 11406190 DOI: 10.1016/S0028-3908(00)00195-7  1
2001 Salamone JD, Correa M, Carlson BB, Wisniecki A, Mayorga AJ, Nisenbaum E, Nisenbaum L, Felder C. Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism. Life Sciences. 68: 2579-84. PMID 11392629 DOI: 10.1016/S0024-3205(01)01055-4  1
1999 Gabel LA, Nisenbaum ES. Muscarinic receptors differentially modulate the persistent potassium current in striatal spiny projection neurons. Journal of Neurophysiology. 81: 1418-23. PMID 10085367  1
1998 Nisenbaum ES, Mermelstein PG, Wilson CJ, Surmeier DJ. Selective blockade of a slowly inactivating potassium current in striatal neurons by (+/-) 6-chloro-APB hydrobromide (SKF82958). Synapse (New York, N.Y.). 29: 213-24. PMID 9635891 DOI: 10.1002/(SICI)1098-2396(199807)29:3<213::AID-SYN3>3.0.CO;2-9  1
1998 Gabel LA, Nisenbaum ES. Biophysical characterization and functional consequences of a slowly inactivating potassium current in neostriatal neurons. Journal of Neurophysiology. 79: 1989-2002. PMID 9535963  1
1996 Nisenbaum ES, Wilson CJ, Foehring RC, Surmeier DJ. Isolation and characterization of a persistent potassium current in neostriatal neurons. Journal of Neurophysiology. 76: 1180-94. PMID 8871229  1
1995 Nisenbaum ES, Wilson CJ. Potassium currents responsible for inward and outward rectification in rat neostriatal spiny projection neurons. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 15: 4449-63. PMID 7790919  1
1994 Nisenbaum ES, Xu ZC, Wilson CJ. Contribution of a slowly inactivating potassium current to the transition to firing of neostriatal spiny projection neurons. Journal of Neurophysiology. 71: 1174-89. PMID 8201411  1
1993 Bernath S, Zigmond MJ, Nisenbaum ES, Vizi ES, Berger TW. Na+ influx through Ca2+ channels can promote striatal GABA efflux in Ca(2+)-deficient conditions in response to electrical field depolarization. Brain Research. 632: 232-8. PMID 8149231 DOI: 10.1016/0006-8993(93)91158-O  1
1993 Nisenbaum ES, Berger TW, Grace AA. Depression of glutamatergic and GABAergic synaptic responses in striatal spiny neurons by stimulation of presynaptic GABAB receptors. Synapse (New York, N.Y.). 14: 221-42. PMID 8105549 DOI: 10.1002/syn.890140306  1
1992 Nisenbaum ES, Grace AA, Berger TW. Functionally distinct subpopulations of striatal neurons are differentially regulated by GABAergic and dopaminergic inputs--II. In vitro analysis. Neuroscience. 48: 579-93. PMID 1351271 DOI: 10.1016/0306-4522(92)90403-O  1
1992 Nisenbaum ES, Berger TW, Grace AA. Presynaptic modulation by GABAB receptors of glutamatergic excitation and GABAergic inhibition of neostriatal neurons. Journal of Neurophysiology. 67: 477-81. PMID 1349038  1
1992 Nisenbaum ES, Berger TW. Functionally distinct subpopulations of striatal neurons are differentially regulated by GABAergic and dopaminergic inputs--I. In vivo analysis. Neuroscience. 48: 561-78. PMID 1318517 DOI: 10.1016/0306-4522(92)90402-N  1
1988 Nisenbaum ES, Orr WB, Berger TW. Evidence for two functionally distinct subpopulations of neurons within the rat striatum. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 8: 4138-50. PMID 3183715  1
1988 Nisenbaum ES, Stricker EM, Zigmond MJ, Berger TW. Spontaneous activity of type II but not type I striatal neurons is correlated with recovery of behavioral function after dopamine-depleting brain lesions. Brain Research. 473: 389-93. PMID 3148358 DOI: 10.1016/0006-8993(88)90872-4  1
1986 Nisenbaum ES, Stricker EM, Zigmond MJ, Berger TW. Long-term effects of dopamine-depleting brain lesions on spontaneous activity of type II striatal neurons: relation to behavioral recovery. Brain Research. 398: 221-30. PMID 3099976 DOI: 10.1016/0006-8993(86)91481-2  1
Show low-probability matches.